PROCEPT BioRobotics Q4 rev $76.4M (+12% YoY), net loss $29.8M; FY26 guidance $390-410M

PROCEPT BioRobotics Corp

2025-FY EPS reported -$1.72 revenue$308,054,000

Q4 total revenue $76.4M (+12% YoY); U.S. procedures ~12,200 (+69% YoY).
Q4 net loss $29.8M vs $18.9M loss; adjusted EBITDA loss $19.0M vs $10.3M.
U.S. install base 718 systems (+42% YoY); handpiece ASP $3,340 (+5% sequentially).
FY 2026 revenue guidance $390-410M (27-33% growth); U.S. procedure growth 39-48%.
FY 2026 gross margin ~65%; operating expenses ~$350M; adj. EBITDA loss $30-17M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.